Furrer Daniela, Jacob Simon, Caron Chantal, Sanschagrin François, Provencher Louise, Diorio Caroline
Cancer Research Center at Laval University, Faculty of Medicine, Laval University, Quebec City, Canada.
Oncology Axis, CHU of Quebec Research Center, Laval University, Quebec City, Canada.
Anticancer Res. 2017 Jun;37(6):3323-3329. doi: 10.21873/anticanres.11701.
Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are common methods for assessment of human epidermal growth factor receptor 2 (HER2) in breast cancer.
In a cohort of 498 consecutive patients with breast cancer, we examined concordance between IHC and FISH for HER2 on tissue microarray (TMA) sections. In a subset of 116 specimens, we examined HER2 concordance from the block used for diagnostics and a randomly-chosen additional block (a proxy of the core biopsy).
Overall concordance between both methods on TMA sections was 93.8% and between HER2, determined on diagnostic and additional blocks, was 93.6% for IHC and 98.0% for FISH.
Since some cases were discordant, we suggest that both methods be used for HER2 assessment. The lower concordance rate between diagnostic and additional blocks using IHC compared to FISH suggests a greater variability of IHC staining across tumor regions than for FISH results.
免疫组织化学（IHC）和荧光原位杂交（FISH）是评估乳腺癌中人表皮生长因子受体2（HER2）的常用方法。
在一组498例连续的乳腺癌患者中，我们检测了组织微阵列（TMA）切片上IHC和FISH检测HER2的一致性。在116个标本的子集中，我们检测了用于诊断的组织块和随机选择的另一个组织块（代表核心活检）中HER2的一致性。
两种方法在TMA切片上的总体一致性为93.8%，在诊断组织块和另一个组织块上检测HER2的一致性方面，IHC为93.6%，FISH为98.0%。
由于部分病例存在不一致情况，我们建议同时使用这两种方法评估HER2。与FISH相比，使用IHC时诊断组织块和另一个组织块之间的一致性较低，这表明与FISH结果相比，IHC染色在肿瘤区域的变异性更大。
